Table 4.

The first 29 high-impact articles with more than 1000 citations based on the total number of citations on Crohn’s disease.

No	Article	Author	Journal	PY	TC	AC
1	Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease	Hugot JP. et al	Nature	2001	4254	184.96
2	A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease	Ogura Y. et al	Nature	2001	3788	164.7
3	Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial	Hanauer SB. et al	Lancet	2002	3167	143.95
4	Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients	Sokol H. et al	Proceedings of the National Academy of Sciences of the United States of America	2008	2758	172.38
5	A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease	Targan SR. et al	New England Journal of Medicine	1997	2642	97.85
6	Infliximab, azathioprine, or combination therapy for Crohn’s disease.	Colombel JF. et al	New England Journal of Medicine	2010	2189	156.36
7	Infliximab for the treatment of fistulas in patients with Crohn’s disease	Present DH. et al	New England Journal of Medicine	1999	2033	81.32
8	Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease	Barrett JC. et al	Nature Genetics	2008	2016	126
9	Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci	Franke A. et al	Nature Genetics	2010	1896	135.43
10	The treatment-naive microbiome in new-onset Crohn’s disease	Gevers D. et al	Cell Host & Microbe	2014	1865	186.5
11	Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: The CHARM trial	Colombel JF. et al	Gastroenterology	2007	1611	94.76
12	Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease	Baert F. et al	New England Journal of Medicine	2003	1592	75.81
13	Reduced diversity of fecal microbiota in Crohn’s disease revealed by a metagenomic approach	Manichanh C. et al	Gut	2006	1575	87.5
14	Infliximab maintenance therapy for fistulizing Crohn’s disease	Sands BE. et al	New England Journal of Medicine	2004	1548	77.4
15	A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1	Hampe J. et al	Nature Genetics	2007	1449	85.24
16	Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis	Rioux JD. et al	Nature Genetics	2007	1396	82.12
17	Vedolizumab as induction and maintenance therapy for Crohn’s disease	Sandborn WJ. et al	New England Journal of Medicine	2013	1312	119.27
18	Crohn’s disease	Baumgart DC.; Sandborn WJ.	Lancet	2012	1305	108.75
19	Predictability of the postoperative course of Crohns-disease	Rutgeerts P. et al	Gastroenterology	1990	1239	36.44
20	Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial	Hanauer SB. et al	Gastroenterology	2006	1220	67.78
21	3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management	Gomollon F. et al	Journal of Crohns & Colitis	2017	1172	167.43
22	High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease	Darfeuille-Michaud A. et al	Gastroenterology	2004	1104	55.2
23	The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management	Dignass A. et al	Journal of Crohns & Colitis	2010	1094	78.14
24	Disparate CD4(+) lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease - Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5	Fuss IJ. et al	Journal of Immunology	1996	1048	37.43
25	Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo	Atreya R. et al	Nature Medicine	2000	1043	43.46
26	Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomized, double-blind placebo-controlled trial	Hueber W. et al	Gut	2012	1043	86.92
27	Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD	Daperno M. et al	Gastrointestinal Endoscopy	2004	1011	50.55
28	A simple classification of Crohn’s disease: report of the working party for the world congresses of gastroenterology, Vienna 1998	Gasche C. et al	Inflammatory Bowel Diseases	2000	1006	41.92

AC = average citations per year, PY = publication year, TC = total citation